By Katherine Hamilton
Pacira Biosciences has authorized a share buyback program of up to $300 million.
The developer of non-opioid pain relievers said Thursday the repurchase program replaces a previous $150 million buyback plan authorized in May 2024.
The new plan expires at the end of December 2026, Pacira said.
"This increased share repurchase authorization underscores the board's confidence in Pacira's growth strategy and our commitment to delivering value to shareholders," Chief Executive Frank Lee said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
April 17, 2025 17:24 ET (21:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.